Genentech's Next Act
245176
Cancer was the biotech's biggest success story. Now to keep growing, it needs to branch out.
578661
Basel, Switzerland, November 30 (ots/PRNewswire) - Roche and Genentech, Inc., announced today that Avastin(TM) (bevacizumab, rhuMAb-VEGF), a new innovative anti-angiogenesis drug, has shown for the first time that it significantly increases survival in
766094
DUBLIN/NEW YORK  - Patients taking an experimental  multiple sclerosis drug developed by Biogen Idec Inc. BIIB.O  and Elan Corp. ELN.I experienced far fewer relapses in a  clinical trial, data that analysts say could give the drug a  dominant market position.
337848
Software giant promises to deliver another tool to fight worms and viruses.
719738
Genentech Inc. on Monday said its colon cancer drug Avastin extended the life of patients when used in combination with a chemotherapy regimen called FOLFOX4 more than the chemotherapy alone in a late stage clinical trial.
400965
Medarex's partner advances one of its compounds into later stage clinical testing.
581460
Genentech announces positive second-quarter results, but investors remain worried.
225228
BOSTON (CBS.MW) - Shares of Genentech were halted on Monday as the company announced that its oncology drug Avastin had been shown to extend the lives of some patients stricken with advanced colorectal cancer.
343153
The packaging and shipping company plans to upgrade readers it&#39;s testing to the next-generation, multiprotocol technology. By Elena Malykhina.
138698
Another schizophrenia drug from the company shows promise in a clinical trial.
293341
Biogen Idec Inc.&#39;s Tysabri drug for multiple sclerosis may reach patients as soon as next week, and doctors said they plan to prescribe it first to patients who are no longer being helped by older medicines.
453741
New drugs that are currently in clinical trials for muscle-wasting diseases could become the next big thing for athletes.
421575
Genentech and OSI Pharmaceuticals won federal approval yesterday to sell Tarceva, a pill to treat lung cancer. The approval by the Food and Drug Administration came well before the agency&#39;s
728268
Genentech Inc., the world&#39;s second- biggest biotechnology company, received a subpoena from the US Attorney&#39;s office in Philadelphia as part of a criminal and civil investigation into marketing of its top-selling drug, Rituxan.
763441
Genentech Inc. (DNA.N: Quote, Profile, Research) on Wednesday posted a 50 percent rise in quarterly profit and raised its full-year earnings forecast on strong sales of
750633
The biotech giant is hit with a subpoena requesting documents related to the promotion of Rituxan, its best-selling drug. Just two days before its third-quarter earnings release, biotechnology pioneer Genentech
66960
Genentech Inc. barely scraped past Wall Street's expectations Monday as the biotech giant renowned for its phenomenal growth posted a 6 percent rise in fourth-quarter profits.